Navigation Links
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Date:5/21/2008

istered to each patient showed a linear correlation with total plasma exposure (AUC) and maximum exposure (Cmax). This is an important finding that supports the ability to reliably titrate oral treprostinil to therapeutic levels.

Intravenous Treprostinil

In Intravenous Treprostinil Effect on Angiopoietin-2 Levels During 12 Weeks of Blinded Therapy: a Study of 11 Biomarkers in PAH, Dr. R. James White presented results of his biomarker study demonstrating that intravenously administered treprostinil sodium (Remodulin(R)) decreased the presence of a specific protein that contributes to PAH -- Angiopoietin-2 -- in 12 of 13 patients. This study was part of the first randomized, placebo-controlled trial of an infused prostacyclin in patients with PAH. The primary endpoint of this randomized, placebo-controlled study, change in 6MW distance, showed an 83-meter improvement as compared to placebo.

In Treatment Effects Following Rapid Switch to IV Treprostinil in Stable PAH Patients, Dr. Omar A. Minai of the Cleveland Clinic presented data from an ongoing single-center, 8-week study of treatment satisfaction of PAH patients who switched from epoprostenol (Flolan(R)) to intravenous Remodulin. Rapid switch from Flolan to Remodulin occurred by directly switching the infusion pump reservoir. Dr. Minai reported that no patients experienced clinical deterioration or change in functional class, and he also observed a favorable impact on quality of life as early as 8 weeks following transition. He noted that time spent by patients on drug preparation decreased by 44 percent with Remodulin as compared to Flolan.

In Multi-Center Experience with Transition to Treprostinil from Inhaled Iloprost in PAH, Dr. Robert Frantz of the Mayo Clinic presented a retrospective chart review that evaluated best practices principally surrounding transitions from inhaled iloprost (Ventavis(R)) to intravenous Remodulin. Medical records were assessed to determine the reason for
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
4. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
6. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
7. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... 2014 Sanomedics International Holdings, Inc. (OTCQB: SIMH) ... Research & Data Services, demand for thermometers is expected ... 2018, as demand for more accurate digital thermometers continues.  ... world,s largest market for thermometers, and one of the ... International Holdings, Inc. Sanomedics International Holdings designs, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS ; ... financial results for the fiscal 2011 second quarter ended December ... 2011. Management has scheduled a conference call ... 2011 (Tuesday, February 15 at 8:30 a.m. AEDT) , ...
... ST. LOUIS, Feb. 4, 2011 K-V Pharmaceutical Company ... today that it has been informed by Hologic, Inc. ... approval for Makena™ (hydroxyprogesterone caproate injection).  Makena, commonly referred ... treatment indicated to reduce the risk of preterm birth ...
Cached Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal 2011 Second Quarter on Monday, February 14, 2011 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
... The experts in this weeks' BMJ, have reported that ... work together to restore faith in drug development//. ... drug Vioxx, produced by Merck and Co. Inc., has ... be open to abuse. ,Vioxx (rofecoxib) ...
... explains - how beneficial traits accumulate in natural populations, but ... two theories have addressed this problem. The theory of hitchhiking ... can become common in natural populations when they "hitch a ... selection. ,Conversely, the theory of kin selection ...
... Drugs that Facilitate and/or Prevent Diabetes//. ... develop new-onset diabetes than those who don’t have hypertension, ... recent weight gain, or stronger family history of diabetes ... have known since 1958 that some drugs used to ...
... children with persistent fluid in the middle ear// need not ... , It is generally believed that ear fluid has to ... study suggests that inserting ear tubes to remove ear fluid ... years of age. This important study was conducted at Children’s ...
Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3Health News:New Approach Needed To Restore Faith in Pharmaceutical Industry 2Health News:Study Explains How Costly Traits Evolve 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 3Health News:Ear Fluid Does Not Impair Development 2Health News:Ear Fluid Does Not Impair Development 3Health News:Ear Fluid Does Not Impair Development 4
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
... Air-Charged Catheters make motility ... Disposable Latitude catheters set up ... cross-contamination. And with every sensor ... by eliminating anatomical irregularities. For ...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: